Health · 4 views
Tumor index can identify breast cancer patients' drug response
Researchers at The Hong Kong Polytechnic University (PolyU) have developed an imaging biomarker, the Tumour Heterogeneity Index (THI), which enables noninvasive assessment of breast cancer patients' response to AKT inhibitors before…
Summary
Researchers at The Hong Kong Polytechnic University (PolyU) have developed an imaging biomarker, the Tumour Heterogeneity Index (THI), which enables noninvasive assessment of breast cancer patients' response to AKT inhibitors before treatment, helping clinicians identify patients most likely to benefit from therapy. The study found that patients with a high THI achieved an estimated pathological complete response (pCR) rate of 56.1%, significantly higher than that of patients with a low THI.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- 'They're Looking for Scapegoats': What We Heard This WeekContinue reading
- The Guardian view on listening to people with learning disabilities: a matter of life and death | EditorialContinue reading
- Vision-language AI agent could help radiologists interpret ultrasounds faster and more accuratelyContinue reading
- Do We Diagnose Too Much Normal Distress?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow